Navigation Links
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Date:7/31/2008

AURORA, Colo., July 31 /PRNewswire/ -- Sierra Neuropharmaceuticals, Inc., a formulator of pharmaceuticals for direct-to-the-brain treatment of neurological diseases, announced a $21.5-million venture capital Series A financing. Co-leads in the funding were HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners. Other investors include High Country Venture and GC&H Investments LLC.

Sierra uses a proprietary drug development process that makes use of standard implantable pumps placed surgically under the skin which deliver drugs directly to the fluid around the brain via a catheter. The approach aims to help patients suffering from severe epilepsy, depression, schizophrenia and other neurological diseases who, until now, have had to treat their conditions by taking drugs orally. "Many current oral therapies are limited in their use due to severe side effects and possible toxicities," says Daniel Abrams, M.D., Sierra's founder, Chief Scientific Officer, and Acting CEO. "For patients, this means they may be denied access to medicines that could otherwise be of great benefit. Even for those drugs that can safely be taken orally, patients often have difficulty maintaining a proper pill regimen and may take only 50-80% of their required dosage. By reformulating existing pharmaceuticals and delivering them via an implanted device, better treatment and new options can be made available to patients."

It is estimated that more than 10 million people in the United States and Europe suffer from severe neurological diseases not adequately treated by current oral medications and would benefit from a new approach. "We think Sierra's new approach offers a broad new pathway for treating neurological diseases," he says, "and an opportunity to enhance patient lives."

To further develop therapies and win FDA approval, Abrams says Sierra will work closely with both pump manufacturers and pharmaceutical companies. The latter, he says, could col
'/>"/>

SOURCE Sierra Neuropharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NuVasive Completes Acquisition of Osteocel Biologics Business
2. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
3. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
4. Accuri Cytometers Completes $13 Million Series C Financing
5. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
6. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
7. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
8. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
9. Boston Scientific Completes Acquisition of CryoCor
10. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
11. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... The U.S. Department of Labor has ... Edwardsville as part of the Trade Adjustment Assistance Community ... co-administered by the Department of Labor and Department of ... Thomas E. Perez and Secretary of Education Arne Duncan ... grants to nearly 270 colleges across the country. ...
(Date:9/30/2014)... available in German . ... Mnchen (TUM) have demonstrated a new kind of building ... future computer chips could be based on three-dimensional arrangements ... enabling technology of the semiconductor industry CMOS fabrication ... researchers and collaborators at the University of Notre Dame ...
(Date:9/30/2014)... Sept. 30, 2014 Nematicide is a ... Nematodes are microscopic parasitic roundworms, found in massive ... other plants and animals. Nematicides have tended to ... properties promoting migration through the soil. A single ... plant-parasitic nematodes. With more than 10,000 species classified, ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Calif. and MONROVIA, Calif., Jan. 6, 2011 Amgen ... today that they will collaborate to develop XmAb ® ... and CD32b.  XmAb5871 is currently in late-stage preclinical development ... Under the terms of the agreement, Amgen has the ...
... SAN FRANCISCO, Jan. 6, 2011 Vista Partners ... Therapeutics, Inc. (Nasdaq: OPXA ) and raised ... Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday ... for the treatment of Multiple sclerosis , is now ...
... 6, 2011 BioInformatics, LLC announces the release of ... Technologies:  Market Insights for Life Science Suppliers (#10-005) This ... respond in a timely fashion to the rapidly changing ... LLC quantifies and characterizes the market for genetic analysis ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2BioInformatics, LLC New Market Report - Genomics Technologies 2
(Date:9/30/2014)... know what goes wrong with your muscles because of age, ... "normal" actually is. That,s where a new research report published ... Journal comes in. In the report, a team ... that can help scientists "see" which genes are active in ... never-before-detected gene activity and that men have approximately 400 more ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... , Jan. 24, 2013 /PRNewswire-iReach/ -- The companion diagnostics ... has become one of the most promising areas within ... companies are now entering the highly attractive market of ... developing a combination product. The explosive M&A trend in ...
... their mother,s diet during gestation and lactation were found to ... than those not exposed to the chemical, researchers at the ... BPA is a chemical most commonly found in the lining ... in many hard plastic bottles, including baby bottles, but many ...
... Researchers at the University of Pittsburgh School of ... key HIV protein. In findings published online today in ... this vulnerable spot could stop the virus from replicating, ... Previous research demonstrated that a small HIV protein ...
Cached Biology News:Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 2Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 3Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 4Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 5Female mice exposed to BPA by mothers show unexpected characteristics 2Female mice exposed to BPA by mothers show unexpected characteristics 3Pitt team finds 'Achilles Heel' of key HIV replication protein 2
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: